Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

COCP

Cocrystal Pharma (COCP)

Cocrystal Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:COCP
DateTimeSourceHeadlineSymbolCompany
20/06/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
20/06/202422:00GlobeNewswire Inc.New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy CowsNASDAQ:COCPCocrystal Pharma Inc
13/05/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
13/05/202422:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
13/05/202422:00GlobeNewswire Inc.Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
08/05/202406:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:COCPCocrystal Pharma Inc
01/05/202422:00GlobeNewswire Inc.Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaNASDAQ:COCPCocrystal Pharma Inc
28/03/202423:00GlobeNewswire Inc.Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
19/03/202423:00GlobeNewswire Inc.Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza ANASDAQ:COCPCocrystal Pharma Inc
02/03/202408:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
09/01/202400:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
05/01/202408:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
05/01/202400:00GlobeNewswire Inc.Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational CandidatesNASDAQ:COCPCocrystal Pharma Inc
03/01/202401:53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:COCPCocrystal Pharma Inc
22/12/202309:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
07/12/202300:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
07/12/202300:00GlobeNewswire Inc.Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza ANASDAQ:COCPCocrystal Pharma Inc
05/12/202300:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
30/11/202300:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
30/11/202300:00GlobeNewswire Inc.Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastNASDAQ:COCPCocrystal Pharma Inc
28/11/202300:00GlobeNewswire Inc.Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023NASDAQ:COCPCocrystal Pharma Inc
14/11/202300:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
14/11/202300:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
14/11/202300:00GlobeNewswire Inc.Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
10/11/202300:00GlobeNewswire Inc.Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastNASDAQ:COCPCocrystal Pharma Inc
31/10/202323:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
31/10/202323:00GlobeNewswire Inc.Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344NASDAQ:COCPCocrystal Pharma Inc
28/09/202322:00GlobeNewswire Inc.Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and CoronavirusNASDAQ:COCPCocrystal Pharma Inc
05/09/202322:00GlobeNewswire Inc.Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment ConferenceNASDAQ:COCPCocrystal Pharma Inc
17/08/202306:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:COCP

Your Recent History

Delayed Upgrade Clock